Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CRHBP | P24387 | 1/20 | 0.31 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.30 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.30 |
| ▸ | GRK5 | P34947 | 1/20 | 0.30 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12207823 | 0.80 | LMNA (0.31) | LMNASMN1; SMN2ALDH1A1HTTTDP1 | |
| SCHEMBL4960221 | 0.76 | PKM (0.37) | PKMLMNASMN1; SMN2ALDH1A1HTT | |
| SCHEMBL27631534 | 0.73 | PKM (0.35) | PKMLMNASMN1; SMN2ALDH1A1HTT | |
| SCHEMBL12291298 | 0.68 | SMN1; SMN2 (0.35) | PKMLMNASMN1; SMN2ALDH1A1HTT | |
| SCHEMBL14019038 | 0.67 | PKM (0.58) | PKMLMNAALDH1A1TDP1CHEK1 | |
| SCHEMBL21719313 | 0.66 | — | — | |
| SCHEMBL12391234 | 0.65 | ALDH1A1 (0.34) | PKMLMNASMN1; SMN2ALDH1A1HTT | |
| SCHEMBL12207829 | 0.63 | ENO1 (0.38) | LMNASMN1; SMN2ALDH1A1HTTCRHBP | |
| SCHEMBL11350079 | 0.63 | PKM (0.35) | PKMLMNASMN1; SMN2ALDH1A1CRHBP | |
| SCHEMBL12208209 | 0.63 | HTT (0.33) | LMNASMN1; SMN2ALDH1A1HTTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132458-A1 | Hypoxia-Activated Anti-Cancer Agents | THRESHOLD PHARMACEUTICALS, INC. (US) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132458-A1 | Hypoxia-Activated Anti-Cancer Agents | HIF1AN, HIF1A, HYOU1 | PKM 2655/4885LMNA 1197/4885SMN1; SMN2 4611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.